Please login to the form below

Not currently logged in
Email:
Password:

KRAS inhibitor

This page shows the latest KRAS inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen aims for first KRAS inhibitor approval in the US

Amgen aims for first KRAS inhibitor approval in the US

The company has filed a new drug application (NDA) with the FDA for the investigational KRAS inhibitor, seeking approval for the treatment of patients with KRAS G12C-mutated locally advanced or ... The CodeBreaK 100 study evaluated the KRAS inhibitor in

Latest news

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    Another company looking to crack the KRAS mutation is Amgen, which recently announced some positive data for its pathfinder KRAS inhibitor AMG 510 in KRAS G12C-positive NSCLC. ... Other competitors in the KRAS inhibitor race include Mirati, Boehringer

  • Amgen buys BeiGene stake for $2.7bn to aid push into China Amgen buys BeiGene stake for $2.7bn to aid push into China

    Included in that part of the deal however is Amgen’s much-anticipated KRAS inhibitor  AMG 510, and its bispecific antibody pipeline featuring anti-BCMA candidate  AMG 420.

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    Unveiled an overall disease control rate of 100%. Amgen has revealed more data for its pathfinder KRAS inhibitor AMG 510, building its case for the drug as a treatment for KRAS ... AMG 510 became the first KRAS inhibitor to show activity in a 35-patient

  • Boehringer bolsters KRAS push with $720m Lupin deal Boehringer bolsters KRAS push with $720m Lupin deal

    Signs of progress in the field are emerging. Boehringer Ingelheim has licensed a MEK inhibitor from India’s Lupin that it intends to pair with its stable of KRAS inhibitors, a ... Other companies including Johnson &Johnson and Mirati are also working

  • So far so good for Amgen's much-anticipated KRAS inhibitor So far so good for Amgen's much-anticipated KRAS inhibitor

    Promise to hit previously 'undruggable' target. Amgen has the first clinical data for its inhibitor of KRAS, a cancer target long though to be almost undruggable despite its promise. ... Amgen is in a race with Mirati Therapeutics to bring a KRAS G12C

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics